LUMRYZ Drug Patent Profile

Which patents cover Lumryz, and when can generic versions of Lumryz launch?

Lumryz is a drug marketed by Avadel Cns and is included in one NDA. There are twenty-nine patents protecting this drug.

This drug has thirty-seven patent family members in ten countries.

The generic ingredient in LUMRYZ is sodium oxybate. There are one thousand four hundred and seventy-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the sodium oxybate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lumryz

A generic version of LUMRYZ was approved as sodium oxybate by AMNEAL on September 10^th, 2025.

Summary for LUMRYZ

International Patents:	37
US Patents:	29
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	1
Patent Applications:	1,492
Drug Prices:	Drug price information for LUMRYZ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LUMRYZ
What excipients (inactive ingredients) are in LUMRYZ?	LUMRYZ excipients list
DailyMed Link:	LUMRYZ at DailyMed

See drug prices for LUMRYZ

Recent Clinical Trials for LUMRYZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Kristina Simonyan	PHASE1

See all LUMRYZ clinical trials

Pharmacology for LUMRYZ

Drug Class	Central Nervous System Depressant
Physiological Effect	Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity

US Patents and Regulatory Information for LUMRYZ

LUMRYZ is protected by twenty-nine US patents and three FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-003	May 1, 2023		RX	Yes	No	10,952,986
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-004	May 1, 2023		RX	Yes	No	11,986,451
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	11,779,557
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-002	May 1, 2023		RX	Yes	No	12,303,478
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-003	May 1, 2023		RX	Yes	No	11,065,224		Y
Avadel Cns	LUMRYZ	sodium oxybate	FOR SUSPENSION, EXTENDED RELEASE;ORAL	214755-004	May 1, 2023		RX	Yes	No	12,138,239		Y

EU/EMA Drug Approvals for LUMRYZ

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
UCB Pharma Ltd	Xyrem	sodium oxybate	EMEA/H/C/000593Treatment of narcolepsy with cataplexy in adult patients.	Authorised	no	no	no	2005-10-13
D&A Pharma	Hopveus	sodium oxybate	EMEA/H/C/004962Substitution treatment for alcohol dependence within a framework of careful medical supervision along with continuous psychosocial support and social rehabilitation. Treatment should be initiated only in patients resistant to existing interventions or in patients for whom existing therapies are contra-indicated or not recommended.	Refused	no	no	no		2020-07-06

International Patents for LUMRYZ

See the table below for patents covering LUMRYZ around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	109376
Australia	2017300845
Australia	2020231916
Australia	2023203055
Australia	2025201830
Australia	2025248712

Supplementary Protection Certificates for LUMRYZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0957929	06C0021	France		PRODUCT NAME: PEGAPTANIB SODIUM; REGISTRATION NO/DATE: EU/1/05/325/001 20060131
0788511	SPC/GB08/036	United Kingdom		PRODUCT NAME: MICAFUNGIN AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF IN PARTICULAR MICAFUNGIN SODIUM; REGISTERED: UK EU/1/08/448/001 20080425; UK EU/1/08/448/002 20080425
1713823	1490064-1	Sweden		PRODUCT NAME: SIMEPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516
0145340	99C0005	Belgium		PRODUCT NAME: FOSPHENYTOIN DISODIUM; NAT. REGISTRATION NO/DATE: NL 23 613 19980806; FIRST REGISTRATION: GB - PL 000 19/0157 19980204
0473687	SPC/GB98/030	United Kingdom		PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204
0290047	SPC/GB97/078	United Kingdom		PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522

LUMRYZ Market Dynamics and Financial Trajectory (2026): Pricing, Demand Drivers, Competitive Pressure, and Exclusivity-to-Revenue Outlook

Last updated: June 12, 2026

LUMRYZ (sodium oxybate) is positioned as a long-duration, once-nightly formulation targeting improved convenience versus Xywav/Xyrem’s split-dose regimen. The financial trajectory over the next 3–5 years hinges on (1) sustained uptake among narcolepsy with cataplexy patients, (2) payer coverage and net price realization as competing sodium oxybate products and emerging sleep-disorder options expand, and (3) the degree to which LUMRYZ captures substitution from existing oxybate users versus converting new prescribers. The key near-term market dynamic is migration from twice-nightly dosing to a once-nightly schedule, balanced against formulary barriers, step edits, and adverse event management.

What is LUMRYZ’s launch-to-revenue profile and what drives near-term sales momentum?

LUMRYZ is a branded sodium oxybate product for narcolepsy with cataplexy, with a pharmacology footprint similar to Xyrem (immediate-release sodium oxybate) but delivered as a longer-duration regimen. The commercial ramp typically follows a staged pattern seen in REMS-heavy CNS launches: initial prescriber education, early patient starts after payer authorization, then broader coverage expansion if persistence and tolerability support continued therapy.

Demand drivers that tend to move LUMRYZ adoption

• Dosing convenience effect: once-nightly administration reduces caregiver burden and may improve adherence versus split dosing.
• Clinical comfort and tolerability management: sodium oxybate is associated with CNS effects; real-world titration outcomes are a primary driver of persistence and prescriber willingness to continue.
• REMS familiarity in payer and prescriber networks: oxybate programs have mature infrastructure; that lowers friction relative to wholly new CNS mechanisms.
• Formulary design: formulary placement, prior authorization criteria, and step therapy requirements determine how quickly prescribers can convert eligible patients.

Revenue ramp pattern to model

• Early phase: sales concentrate at high-volume sleep centers with strong payer navigation and patient access teams.
• Growth phase: penetration spreads as payers normalize coverage and physicians expand criteria to patients who previously stayed on Xyrem or Xywav.
• Maturation: incremental growth depends on continued label coverage expansion in practice patterns and sustained persistence, not just new prescriptions.

How does LUMRYZ compete with Xyrem and Xywav and what are the substitution risks?

The competitive set for LUMRYZ is dominated by oxybate incumbents and the broader narcolepsy-with-cataplexy treatment landscape. Sodium oxybate products are the primary disease-modifying option category, and switching between oxybate formulations is common when dosing convenience and payer economics align.

Key substitution mechanics

• Switching from Xyrem/Xywav: LUMRYZ’s uptake depends on patient and prescriber willingness to convert, which correlates with:
  • perceived tolerability differences during titration,
  • logistics (nighttime schedule),
  • insurance approval speed, and
  • copay support and financial assistance availability.
• Avoided switching: if payers require that patients fail or demonstrate suboptimal response on one incumbent, LUMRYZ starts slower.
• Overhang from incumbent rebates: if Xyrem or Xywav contracts offer aggressive net pricing, LUMRYZ must overcome that gap to gain share.

Commercial implication

If LUMRYZ is adopted mainly as a switch from incumbents, revenue depends on how much of the gross prescription volume it can capture without triggering payer pushback. If it grows largely by converting new-to-oxybate patients, it can expand total category volume, but that tends to be slower.

What is the payer and access landscape for LUMRYZ and how does it shape net price?

Payer coverage is the main determinant of net sales trajectory in REMS-class CNS products. For LUMRYZ, the practical levers are prior authorization, formulary tiering, and patient financial assistance. Net price outcomes can diverge materially from list price depending on contracting and manufacturer rebate strategies.

Access factors that typically govern early and mid-period net sales

• Prior authorization speed: delays compress first-year revenue, especially during the ramp.
• Step edits: required failure on another oxybate slows conversion.
• Patient affordability programs: copay assistance can increase persistence and reduce abandonment risk.
• REMS and distribution logistics: consistent patient onboarding can reduce drop-off rates and stabilize prescribing.

Pricing outcome expectation

A branded-to-branded shift typically produces a net pricing trade-off: manufacturers often fund rebate and assistance to gain formulary position while protecting gross-to-net margins. LUMRYZ’s financial performance therefore depends on whether it can achieve share without requiring unsustainably high net concessions.

When does LUMRYZ face exclusivity and patent-expiration pressure, and how does that affect revenue forecasts?

Long-duration sodium oxybate products are subject to layered IP including active ingredient, formulation, and method-of-use claims. The revenue impact timeline is driven by:

• hard patent expiration (generic entry risk),
• regulatory exclusivities that block labeling approval even if patents expire, and
• settlement outcomes in generic development.

Commercial forecasting framework

Revenue risk typically rises when:

• multiple exclusivity clocks near the end,
• Paragraph IV ANDA candidates emerge with a credible entry plan,
• litigation timelines compress the window to settlement.

For sodium oxybate products, the market also remains sensitive to REMS and controlled substance handling requirements, which can extend practical launch friction even after legal exclusivity ends.

What is the Orange Book status of LUMRYZ and how many patents cover it?

Orange Book coverage normally includes both drug-substance and product-related patents, with additional method-of-use patents if applicable. Patent count and remaining life determine how many “shots on goal” a generic challenger can target, and how much leverage exists for settlements.

Featured snippet answer

LUMRYZ’s Orange Book coverage must be evaluated claim-by-claim because:

• formulation and dosing regimen patents can block “design-around” pathways,
• method-of-use claims can constrain label substitutions,
• multiple patents expiring in different years create a staged risk curve.

What generic entry risks exist for LUMRYZ (ANDA Paragraph IV) and what settlement patterns are typical?

Paragraph IV challenges drive generic entry risk, but the actual launch often depends on:

• court timing and stays,
• negotiated settlement terms that may include delayed launch dates and scope limits,
• whether the generic can secure label carve-outs that avoid infringing claims.

Why oxybate litigation can change market dynamics

• Injunction leverage: if a court blocks launch, the generic timeline resets.
• Stays under Hatch-Waxman: first-filing ANDAs can remain stayed while litigation proceeds.
• Settlement scope: settlements can restrict launch until a date or limit dosage forms and titration claims.

How strong is LUMRYZ’s patent estate and what does that imply for durability of sales?

A strong patent estate supports revenue durability by:

• delaying generic labeling approvals,
• increasing the expected cost and uncertainty of generic entry,
• incentivizing brand-to-brand switching only among patented products rather than generics.

Investor-style durability indicators

• Number of unexpired patents across multiple categories (drug substance, formulation, method of use).
• Concentration of remaining life: if many key patents cluster with a single expiration date, risk can jump late. If staggered, risk can be more continuous.
• Litigation history: prior settlements and court outcomes inform how aggressively challengers pursue.

What formulation and method-of-use patents matter most for LUMRYZ’s design-around risk?

For sodium oxybate, generic design-around strategies often target:

• drug-release profile,
• dosing schedule structure,
• formulation excipients and manufacturing controls,
• claimed method-of-use instructions tied to titration and regimen.

Design-around pressure points

• Long-duration delivery specifics: changes to release characteristics can trigger formulation infringement.
• Regimen language in labeling: even if a generic matches pharmacokinetics, it may still infringe method-of-use claims depending on claim scope.
• Manufacturing method claims: process patents can constrain production even if formulation looks superficially different.

What FDA regulatory status and market access constraints apply to LUMRYZ?

LUMRYZ’s clinical development and approval are shaped by REMS requirements typical for sodium oxybate due to abuse potential and serious adverse events. Regulatory status affects commercial speed through:

• distribution onboarding,
• prescriber qualification workflows,
• patient screening and monitoring requirements.

Pathway relevance

Even with legal freedom, the practical time-to-patient depends on:

• REMS enrollment completion,
• pharmacy fulfillment setup,
• prescriber and institutional comfort with the monitoring workflow.

How does LUMRYZ’s financial trajectory compare with other narcolepsy drugs on revenue growth rate and sustainability?

LUMRYZ’s competitive set includes stimulants and wake-promoting agents for excessive daytime sleepiness, plus other narcolepsy symptom therapies. However, oxybate products typically carry the largest monetization potential within narcolepsy with cataplexy because they treat cataplexy and related outcomes and are less substitutable across the category.

Relative financial expectations

• Oxybate brands: higher sales per patient due to long-term therapy and stronger symptom-target overlap.
• Symptom-focused non-oxybate therapies: may experience more churn and payer-driven switching based on tolerability, coverage, and off-label perceptions.

If LUMRYZ captures share from Xyrem/Xywav, it can show faster category share gains than non-oxybate competitors, but net margin depends on contracting intensity.

What commercial milestones should track LUMRYZ’s next 12–24 months?

High-signal milestones include:

• Formulary coverage expansion: inclusion on larger commercial formularies and reduced step edits.
• Patient persistence: continuation rates at 6 and 12 months.
• Adverse event management and discontinuation rates: if discontinuations drop, gross-to-net improves via higher refill volumes.
• Distribution and REMS throughput: reduction in onboarding time for new patients.

Key Takeaways

• LUMRYZ’s market dynamics center on switching convenience and payer access design more than on a new mechanism.
• The financial trajectory is most sensitive to net price (rebates and contracting), persistence, and conversion speed from existing oxybate users.
• Generic entry risk is driven by Orange Book patent coverage and Paragraph IV litigation outcomes, with oxybate RE MS logistics adding practical launch friction even after legal hurdles clear.
• Revenue durability depends on whether LUMRYZ’s formulation and method-of-use patent layers constrain design-around efforts and how quickly payers can shift patients back to incumbents or to future entrants.

FAQs

1. What coverage restrictions commonly limit early adoption of LUMRYZ in narcolepsy with cataplexy?
2. How do dosing convenience and titration tolerability translate into persistence for sodium oxybate brands like LUMRYZ?
3. What is the typical impact of Paragraph IV litigation on oxybate category pricing and pharmacy channel behavior?
4. How do rebate structures and copay assistance affect LUMRYZ gross-to-net and profitability versus Xyrem/Xywav?
5. What manufacturing or formulation changes are most likely to create generic design-around risk for long-duration oxybate products?

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (FDA). https://www.accessdata.fda.gov/scripts/cder/ob/.
2. FDA. LUMRYZ (sodium oxybate) prescribing information and REMS program information. (FDA Labeling). https://www.accessdata.fda.gov/scripts/cder/daf/.